Evaluate BHVN stock safety — financial health, volatility, institutional backing, and risk factors.

What are the risks of investing in BHVN? | Glauxie AI

Q: What are the risks of investing in BHVN?

Biohaven Ltd. (BHVN) operates in the Biotechnology industry (Healthcare sector). The company is led by CEO Vladimir Coric. Biohaven Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on development of therapies for neurological and immunoscience diseases that can change current treatment paradigms. Employees: 15,000.

Q: How much debt does BHVN have?

Review BHVN total debt, debt-to-equity ratio, interest coverage, and leverage trends.

Q: Is BHVN a good long-term investment?

Evaluate BHVN as a long-term investment using fundamental scores, growth metrics, and risk assessment.

What are the risks of investing in BHVN?

🦉

Biohaven Ltd. (BHVN)

Company Overview

Sector / IndustryHealthcare / Biotechnology

CEOVladimir Coric

Biohaven Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on development of therapies for neurological and immunoscience diseases that can change current treatment paradigms.

Key Executives

Name	Title
Bruce D. Car DACVP	Chief Scientific Officer
Clifford Bechtold	President, GM of Biohaven Ireland & Chief Compliance Officer
Deb Young	Senior Director of Regulatory Affairs & Operations
George C. Clark	Vice President & Chief Accounting Officer
Jennifer Porcelli	Vice President of Investor Relations
John McGill	Chief Technology Officer

Financial Health

Risk Assessment

Weather Score0/100

RegimeN/A

BHVN Profile Financials

Is BHVN stock safe? How much debt does BHVN have? Is BHVN a good long-term investment?